NasdaqGS:TEMLife Sciences
Tempus AI (TEM) Valuation Check As FDA Approval And New AI Tools Shape Growth Expectations
Tempus AI (TEM) has been busy, with FDA approval for its xT CDx tumor-only sequencing platform, new hematologic cancer testing, and upgraded AI tools for clinicians and drug developers drawing fresh attention to the stock.
See our latest analysis for Tempus AI.
Despite a steady flow of new AI tools, clinical tests, and research initiatives in recent weeks, Tempus AI’s short term share price return has been weak. The stock closed at US$48.82, with the year to date share price return down...